The United States (U.S.) Food and Drug Administration (FDA) today approved Celltrion’s INFLECTRA™ (biosimilar infliximab) across all eligible indications of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

BMO Capital Reiterates Outperform on Pfizer (PFE) Following Allergan Merger TerminationApril 6, 2016 10:42 AM FDA Approves INFLECTRA™ (Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible IndicationsApril 5, 2016 5:34 PM FDA Approves Remicade Biosimilar, Inflectra (PFE) (JNJ_April 5, 2016 4:02 PM